EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effectiveness of direct‐acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: A national real‐world cohort (REACH‐C)

Jessica Hudson-Buhagiar, Joanne Carson iD, Scott Monaghan, Patricia Collie, Renjy Nelson, Helen Van Gessel, Phillip Read, Josh Hanson iD, Robert Monaghan, Gail Matthews, Gregory J Dore, Marianne Martinello iD und 1 weitere

Journal of Viral Hepatitis · 2023

DOI: 10.1111/jvh.13803 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2023. Verfasst von Jessica Hudson-Buhagiar und 12 weiteren Autor:innen. Beteiligte Einrichtung: Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Hepatitis C. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aboriginal and Torres Strait Islander peoples experience a disproportionate burden of hepatitis C virus (HCV) infection. This study assessed the effectiveness of direct‐acting antiviral (DAA) therapy among Aboriginal peoples in the three years following universal access in Australia. REACH‐C, a national multicentre prospective cohort study, evaluated HCV treatment outcomes from sequential DAA initiations across 33 health services between March 2016 and June 2019. DAA effectiveness was assessed by sustained virological response (SVR) in the total (full analysis set) and effectiveness (modified analysis set excluding those lost to follow‐up) populations. Overall, 915 (10%) Aboriginal and 8095 (90%) non‐Indigenous people commenced DAA therapy, of whom 30% and 16% reported current injecting drug use and 73% and 42% were treated in primary care, respectively. SVR in the total and effectiveness populations was 74% and 94% among Aboriginal people and 82% and 94% among non‐Indigenous people, with loss to follow‐up contributing to lower SVR in the total population analysis (22% Aboriginal, 13% non‐Indigenous). Among Aboriginal people, returning for follow‐up was positively associated with older age (aOR 1.20; 95% CI 1.04, 1.39) and SVR was negatively associated with cirrhosis (aOR 0.39; 95% CI 0.19, 0.80) and prior DAA treatment (aOR 0.14; 95% CI 0.04, 0.49). Factors reflecting higher vulnerability or inequity were not associated with returning for testing or SVR. DAA therapy was highly effective among Aboriginal peoples with HCV treated through primary and tertiary services. Tailored community‐led interventions are necessary to optimize follow‐up and engagement. Sustained DAA uptake and equitable access to care, treatment and prevention are required for HCV elimination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis C, ChronicHepatitis CHumansAntiviral AgentsHepacivirusAustralian Aboriginal and Torres Strait Islander PeoplesProspective StudiesAustralia

Stichwörter der Autor:innen

direct-acting antiviralsfirst nationshepatitis Cindigenousloss to follow-upprimary care

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.
  • Bulgarr Ngaru Medical Aboriginal Corporation, Grafton, New South Wales, Australia.
  • The Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
  • Western Australia Country Health Service, Albany, Western Australia, Australia.
  • Kirketon Road Centre, Sydney, New South Wales, Australia.
  • Cairns Hinterland and Hospital Health Service, Cairns, Queensland, Australia.

ORCID-Profile: Joanne Carson, Josh Hanson, Marianne Martinello

Zitieren

APA

Hudson-Buhagiar, J., Carson, J., Monaghan, S., Collie, P., Nelson, R., Van Gessel, H., Read, P., Hanson, J., Monaghan, R., Matthews, G., Dore, G. J., Martinello, M., & REACH-C study group (2023). Effectiveness of direct‐acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: A national real‐world cohort (REACH‐C). Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.13803

Vancouver

Hudson-Buhagiar J, Carson J, Monaghan S, Collie P, Nelson R, Van Gessel H, et al. Effectiveness of direct‐acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: A national real‐world cohort (REACH‐C). Journal of Viral Hepatitis. 2023. doi:10.1111/jvh.13803

BibTeX
@article{HudsonBuhagiar2023,
  author = {Hudson-Buhagiar, Jessica and Carson, Joanne and Monaghan, Scott and Collie, Patricia and Nelson, Renjy and Van Gessel, Helen and Read, Phillip and Hanson, Josh and Monaghan, Robert and Matthews, Gail and Dore, Gregory J and Martinello, Marianne and REACH-C study group, REACH-C study group},
  title = {Effectiveness of direct‐acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: A national real‐world cohort (REACH‐C)},
  journal = {Journal of Viral Hepatitis},
  year = {2023},
  doi = {10.1111/jvh.13803}
}
Kostenlos starten →